Panitumumab can safely and effectively be substituted for cetuximab in the treatment of BRAF V600Emut metastatic colorectal cancer (mCRC) - A case series
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:174 |
|---|---|
| Enthalten in: |
European journal of cancer (Oxford, England : 1990) - 174(2022) vom: 01. Okt., Seite 37-39 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rausch, Christian [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
6A901E312A |
|---|
| Anmerkungen: |
Date Completed 20.09.2022 Date Revised 08.11.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ejca.2022.07.013 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34488743X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34488743X | ||
| 003 | DE-627 | ||
| 005 | 20231226023812.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ejca.2022.07.013 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1149.xml |
| 035 | |a (DE-627)NLM34488743X | ||
| 035 | |a (NLM)35970034 | ||
| 035 | |a (PII)S0959-8049(22)00438-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rausch, Christian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Panitumumab can safely and effectively be substituted for cetuximab in the treatment of BRAF V600Emut metastatic colorectal cancer (mCRC) - A case series |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.09.2022 | ||
| 500 | |a Date Revised 08.11.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Panitumumab |2 NLM | |
| 650 | 7 | |a 6A901E312A |2 NLM | |
| 650 | 7 | |a BRAF protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins B-raf |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins p21(ras) |2 NLM | |
| 650 | 7 | |a EC 3.6.5.2 |2 NLM | |
| 650 | 7 | |a Cetuximab |2 NLM | |
| 650 | 7 | |a PQX0D8J21J |2 NLM | |
| 700 | 1 | |a Schwicht, Charlotte |e verfasserin |4 aut | |
| 700 | 1 | |a Doedens, Daphne |e verfasserin |4 aut | |
| 700 | 1 | |a Forstpointner, Roswitha |e verfasserin |4 aut | |
| 700 | 1 | |a Westphalen, Christoph Benedikt |e verfasserin |4 aut | |
| 700 | 1 | |a Heinemann, Volker |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of cancer (Oxford, England : 1990) |d 1991 |g 174(2022) vom: 01. Okt., Seite 37-39 |w (DE-627)NLM012602779 |x 1879-0852 |7 nnns |
| 773 | 1 | 8 | |g volume:174 |g year:2022 |g day:01 |g month:10 |g pages:37-39 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejca.2022.07.013 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 174 |j 2022 |b 01 |c 10 |h 37-39 | ||